LLY Stock: Unusual Options Activity Flags Both Upside and Downside Bets as Eli Lilly Trades Near $955

By TrendSpider Editor

Eli Lilly and Company is drawing attention in the options market today, with two unusual contracts totaling $2,525,000 in combined premium activity spotted on April 9, 2026. The stock is trading at $955.67, up 0.25% on the session, sitting in the middle of its 52-week range of $623.79 to $1,133.95.

LLY Stock: Unusual Options Activity Flags Both Upside and Downside Bets as Eli Lilly Trades Near $955

Eli Lilly and Company is drawing attention in the options market today, with two unusual contracts totaling $2,525,000 in combined premium activity spotted on April 9, 2026. The stock is trading at $955.67, up 0.25% on the session, sitting in the middle of its 52-week range of $623.79 to $1,133.95. The divergence between a near-term call and a longer-dated put suggests traders are positioning for meaningful price action in both directions over different time horizons.

Key Drivers of the LLY Stock Move

The options setup reflects a market that is not fully decided on Eli Lilly's trajectory. The near-term call activity implies some traders expect a catalyst or continued momentum toward the upper half of the 52-week range, which peaked at $1,133.95. Meanwhile, the outsized open interest footprint on the long-dated put indicates someone is either protecting a large equity position or making a calculated bearish wager with a wide time horizon. Eli Lilly remains one of the most closely watched names in large-cap pharma, driven by sustained investor focus on its GLP-1 portfolio including tirzepatide, and any clinical, regulatory, or competitive developments in that space could serve as the catalyst that resolves this split positioning.

LLY Unusual Options Activity

Total unusual options premium today reached $2,525,000 across both contracts. The call side dominates in raw premium and contract size, while the put side stands out for its extraordinary open interest ratio, indicating today's volume is more than double the existing open interest in that specific contract.

LLY Seasonality

April and the early second quarter have historically been an active period for large-cap pharmaceutical names as the industry conference season ramps up and Q1 earnings results begin to surface. With the near-term call expiring in June, the timing aligns with a window that could capture any late spring clinical or earnings catalysts for Eli Lilly.

LLY Relative Performance

Eli Lilly's current price of $955.67 represents a gain of approximately 53% from the 52-week low of $623.79, though the stock remains roughly 15.7% below its 52-week high of $1,133.95. The modest 0.25% gain on today's session suggests the broader equity market's recovery from recent volatility is being reflected in LLY, though the stock has not reclaimed its peak levels from the past year, indicating that near-term upside conviction remains contested among market participants.